InVenis Biotherapies receives support from the Lille University Foundation 


InVenis Biotherapies, a Lille-based biotech start-updeveloping platelet lysate based-regenerative medicine dedicated to the treatment of various brain diseases, has received a Lille University Foundation investment to develop its innovative treatment for amyotrophic lateral sclerosis (ALS).  

ALS is a rare neurodegenerative disease, affecting 250,000 people worldwide. ALS is a particularly severe pathology with a median survival of 3 years after diagnosis and currently incurable. The Invenis Biotherapies team is using the human body's natural system contained in platelets to develop a treatment for ALS. This project is the result of more than ten years of academic and industrial research conducted by the team of Prof. David Devos (Medical Pharmacology, CHU-Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172, France) and Prof. Thierry Burnouf (Vice Dean, College of Biomedical Engineering, Taipei Medical University, Taiwan).

"Platelets are known for their role in coagulation but they also play a vital role in wound healing and tissue regeneration. To be able to use this potential in neurodegenerative diseases is a great hope." commented Prof. Thierry Burnouf, co-founder of InVenis Biotherapies. 

Thanks to the scientific excellence and social value of its research, Invenis Biotherapies now benefits from the support of Lille University Foundation and can accelerate the development of its biotherapeutic treatment. 

"We hope to have an impact on the evolution of ALS and, in the longer term, to be able to treat other neurodegenerative diseases such as Alzheimer's or Parkinson's diseases” Dr Matthieu FISICHELLA, CEO & Co-founder InVenis Biotherapies.